ReviewCurrent hypertension reports2022
Cardiovascular Disease Risk Reduction and Body Mass Index.
Review in Current hypertension reports, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 14 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
14 citing papers in PubMed, 1 synthesis or guideline pooled it, 24 citations in OpenAlex.
- Interventions implemented through sporting organisations for promoting healthy behaviour or improving health outcomes.The Cochrane database of systematic reviews · 2025Pooled it
- Associations between metabolic obesity phenotypes and incident cardiovascular disease in middle-aged and elderly Chinese individuals.BMC cardiovascular disorders · 2026Article
- Article
- Motor Capabilities and Body Composition in Health vs. Non-Health University Students: A Pilot Study.Life (Basel, Switzerland) · 2025Article
- Body mass index and mortality after elective open abdominal aortic aneurysm repair in a fifteen year multicenter cohort study.Scientific reports · 2025Article
- Prognostic value of the neutrophil to lymphocyte ratio for cardiovascular diseases: research progress.American journal of translational research · 2025Review
- Development and interpretation of a machine learning model for predicting body mass index in Chinese adolescents: a prospective cohort study.Frontiers in public health · 2025Article
- Self-reported sleep duration and quality and cardiovascular diseases among middle-aged and older Chinese: A 7-year longitudinal cohort study.Journal of clinical hypertension (Greenwich, Conn.) · 2024Article
- Age-specific heterogeneity of genetic susceptibility to cardiovascular disease might have opposite outcomes depending on the presence of prediabetes.World journal of diabetes · 2024Article
- Genetic associations of childhood and adult BMI on chronic heart failure and ischemic stroke: A Mendelian randomization.International journal of cardiology. Heart & vasculature · 2024Article
- Lipid-Lowering Therapy in PURE Poland Cohort Study.Journal of clinical medicine · 2023Article
- Transcriptome-wide association studies: recent advances in methods, applications and available databases.Communications biology · 2023Review
- Reduction of NADPH oxidase 4 in adipocytes contributes to the anti-obesity effect of dihydroartemisinin.Heliyon · 2023Article
- The Related Metabolic Diseases and Treatments of Obesity.Healthcare (Basel, Switzerland) · 2022Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors at 3 institutions in 2 countries.
Funding
No grant is acknowledged in the PubMed record.
Abstract
purpose of reviewAnti-hypertensive and lipid lowering therapy addresses only half of the cardiovascular disease risk in patients with body mass index > 30 kg/m RECENT
findingsObesity-related insulin resistance, vascular endothelium dysfunction, increased sympathetic nervous system/renin-angiotensin-aldosterone system activity, and glomerulopathy lead to type 2 diabetes, coronary atherosclerosis, and chronic disease kidney disease that besides hypertension and dyslipidemia increase cardiovascular disease risk. Obesity increases cardiovascular disease risk through multiple pathways. Optimal reduction of cardiovascular disease risk in patients with obesity is likely to require therapy targeted at both obesity and obesity-associated conditions.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.